Matrix metalloproteinases and proinflammatory cytokines (MMP/Cytokine modulation)

This target profile describes the broad-spectrum, non-specific modulation of Matrix Metalloproteinases (MMPs) and proinflammatory cytokines, a therapeutic strategy often employed in chronic inflammatory and degenerative diseases. MMPs are a family of zinc-dependent endopeptidases responsible for the degradation of extracellular matrix components, while proinflammatory cytokines like TNF-alpha and IL-1 beta serve as key upstream regulators of these enzymes (Source: UniProt, P08253; PubMed, PMC2844788). Unlike targeted biologics that bind to a single receptor, this approach involves indirect mechanisms such as the chelation of essential metal ions (Zn2+ and Ca2+) required for MMP catalytic activity and the suppression of cytokine-induced gene expression (Source: PubChem, CID 5467120). This multi-faceted modulation is characteristic of drugs like sub-antimicrobial dose doxycycline, which is used to treat periodontitis by reducing tissue destruction without exerting antibiotic pressure (Source: FDA, NDA 050744). By dampening the overactive inflammatory-proteolytic axis, this strategy aims to restore tissue homeostasis in conditions where specific single-target inhibition has proven insufficient or toxic. It is particularly relevant in diseases where excessive matrix degradation and persistent inflammation drive pathology, such as rosacea and rheumatoid arthritis.

Other names

MMPsMatrixinsPro-inflammatory cytokinesInflammatory mediatorsMatrix metallopeptidases

Indirect modulation through the chelation of divalent metal ions (zinc and calcium) necessary for enzyme activity and the downregulation of proinflammatory cytokine expression via transcriptional pathways (Source: PubMed, 11199164).